AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V
globenewswire.com
news
2022-10-20 00:00:00

The transaction reflects a pre-money equity value of $400 million for AUM BiosciencesTransaction is expected to provide $69 million of gross proceeds (assuming no redemptions by Mountain Crest stockholders) Broad pipeline of drug candidates across multiple oncology programs; two lead clinical-stage candidates addressing a combined market opportunity of $10+ billion in metastatic colorectal cancer, and TRK Fusion and mutation cancersMr. Vishal Doshi will continue to lead as the CEO of the publicly traded holding entity; a Mountain Crest representative will join the Board of Directors Company to expand US operations and clinical programs SINGAPORE and NEW YORK, Oct.
